Skip to content
2000
image of CYP2C19 Genetic Variants Associated with Clopidogrel Resistance and Major Adverse Cardiovascular Events in Vietnamese Patients Undergoing Percutaneous Coronary Intervention
file format pdf download PDF

Abstract

Introduction

Acute coronary syndrome (ACS) is a leading cause of death, and clopidogrel resistance remains a major challenge in its treatment. This study aims to determine the impact of CYP2C19 genetic variants on clopidogrel resistance (CR) and major adverse cardiovascular events (MACEs) in Vietnamese patients undergoing percutaneous coronary intervention (PCI).

Methods

We carried out a descriptive cross-sectional study, supplemented by a prospective longitudinal follow-up, on 113 ACS patients undergoing PCI with drug-eluting stent implantation at the Department of Cardiology, Military Hospital 103, from January 2015 to May 2018. We excluded patients with a decreased platelet count (< 100 × 10^9/L), a decreased estimated glomerular filtration rate (< 15 mL/min), ongoing bleeding, coagulation disorders, planned or recent surgery, or a coexisting malignancy. CR was defined as platelet aggregation ≥ 46%. The Amplification Refractory Mutation System (ARMS)-PCR was used to determine the CYP2C19 genotype and phenotype. Causes leading to patient readmission, such as angina, recurrent acute myocardial infarction, stroke, or death within 30 days, were recorded as MACEs.

Results

The rate of CR was 29.9% (33/113 patients), and the incidence of MACEs was 15.9% (18/113 patients). The frequencies of CYP2C192 and CYP2C193 polymorphisms, as well as the PM CYP2C19 phenotype, were higher in the CR and MACE groups compared to those without these characteristics ( = 0.24, 0.006, and < 0.001, respectively). The PM CYP2C19 phenotype was predictive of 30-day MACEs in ACS patients undergoing PCI with stent implantation ( < 0.001).

Discussion

Our findings demonstrate a strong association between CYP2C19 PM phenotypes and increased risks of both clopidogrel resistance and 30-day MACEs in Vietnamese ACS patients undergoing PCI. These results underscore the clinical significance of CYP2C19 genotyping in optimizing antiplatelet therapy and enhancing outcomes in this patient population.

Conclusion

PM CYP2C19 phenotypes were associated with an increased risk of CR and MACEs in Vietnamese patients undergoing PCI with stent implantation.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/chddt/10.2174/011871529X384209250812065418
2025-08-19
2025-11-01

  • From This Site

    /content/journals/chddt/10.2174/011871529X384209250812065418
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/chddt/10.2174/011871529X384209250812065418/BMS-CHDDT-2025-2.html?itemId=/content/journals/chddt/10.2174/011871529X384209250812065418&mimeType=html&fmt=ahah

References

  1. Smith J.N. Negrelli J.M. Manek M.B. Hawes E.M. Viera A.J. Diagnosis and management of acute coronary syndrome: An evidence-based update. J. Am. Board Fam. Med. 2015 28 2 283 293 10.3122/jabfm.2015.02.140189 25748771
    [Google Scholar]
  2. Bergmark B.A. Mathenge N. Merlini P.A. Lawrence-Wright M.B. Giugliano R.P. Acute coronary syndromes. Lancet 2022 399 10332 1347 1358 10.1016/S0140‑6736(21)02391‑6 35367005
    [Google Scholar]
  3. Jones D.E. Braun M. Kassop D. Acute coronary syndrome: Common complications and conditions That Mimic ACS. FP Essent. 2020 490 29 34 32150366
    [Google Scholar]
  4. Timmis A. Townsend N. Gale C. Grobbee R. Maniadakis N. Flather M. Wilkins E. Wright L. Vos R. Bax J. Blum M. Pinto F. Vardas P. Goda A. Demiraj A.F. Weidinger F. Metzler B. Ibrahimov F. Pasquet A.A. Claeys M. Thorton Y. Kusljugic Z. Smajic E. Velchev V. Ivanov N. Antoniades L. Agathangelou P. Táborský M. Gerdes C. Viigima M. Juhani P.M. Juilliere Y. Cattan S. Aladashvili A. Hamm C. Kuck K-H. Papoutsis K. Bestehorn K. Foussas S. Giannoulidou G. Varounis C. Kallikazaros I. Kiss R.G. Czétényi T. Becker D. Gudnason T. Kearney P. McDonald K. Rozenman Y. Ziv B. Bolognese L. Luciolli P. Boriani G. Berkinbayev S. Rakisheva A. Mirrakhimov E. Erglis A. Jegere S. Marinskis G. Beissel J. Marchal N. Kedev S. Xuereb R.G. Tilney T. Felice T. Popovici M. Bax J. Mulder B. Simoons M. Elsendoorn M. Steigen T.K. Atar D. Kalarus Z. Tendera M. Cardoso J.S. Ribeiro J. Mateus C. Tatu-Chitoiu G. Seferovic P. Beleslin B. Simkova I. Durcikova P. Belicova V. Fras Z. Radelj S. Gonzalez Juanatey J.R. Legendre S. Braunschweig F. Kaufmann U.P. Rudiger-Sturchler M. Tokgozoglu L. Unver A. Kovalenko V. Nesukay E. Naum A. de Courtelary P.T. Martin S. Sebastiao D. Ghislain D. Bardinet I. Logstrup S. European society of cardiology: Cardiovascular disease statistics 2017. Eur. Heart J. 2018 39 7 508 579 10.1093/eurheartj/ehx628 29190377
    [Google Scholar]
  5. Levine G.N. Bates E.R. Bittl J.A. Brindis R.G. Fihn S.D. Fleisher L.A. Granger C.B. Lange R.A. Mack M.J. Mauri L. Mehran R. Mukherjee D. Newby L.K. O’Gara P.T. Sabatine M.S. Smith P.K. Smith S.C. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J. Am. Coll. Cardiol. 2016 68 10 1082 1115 10.1016/j.jacc.2016.03.513 27036918
    [Google Scholar]
  6. Giantini A. Timan I.S. Dharma R. Sukmawan R. Setiabudy R. Alwi I. Harahap A.R. Listiyaningsih E. Partakusuma L.G. Tansir A.R. Sahar W. Hidayat R. The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention. Front. Cardiovasc. Med. 2023 9 1027892 10.3389/fcvm.2022.1027892 36843628
    [Google Scholar]
  7. Holmes D.R. Dehmer G.J. Kaul S. Leifer D. O’Gara P.T. Stein C.M. ACCF/AHA clopidogrel clinical alert: Approaches to the FDA “Boxed warning”. Circulation 2010 122 5 537 557 10.1161/CIR.0b013e3181ee08ed 20585015
    [Google Scholar]
  8. Ali Z.O. Bader L. Mohammed S. Arafa S. Arabi A. Cavallari L. Langaee T. Mraiche F. Rizk N. Awaisu A. Shahin M.H. Elewa H. Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation. Pharmacogenet. Genomics 2022 32 5 183 191 10.1097/FPC.0000000000000469 35389962
    [Google Scholar]
  9. Kambhampati N.T. Ahamed H. K K V. David S. Hakeem S.C. Pillai G. Kartha N. Cytochrome P450 2C19 polymorphisms and its association with major adverse cardiac events in post-coronary intervention patients on clopidogrel in the tertiary care center. Cureus 2023 15 2 34737 10.7759/cureus.34737 36913219
    [Google Scholar]
  10. Biswas M. Rahaman S. Biswas T.K. Ibrahim B. Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: Meta-analysis. Int. J. Clin. Pharm. 2021 43 5 1360 1369 10.1007/s11096‑021‑01261‑y 33774763
    [Google Scholar]
  11. Gurbel P.A. Antonino M.J. Bliden K.P. DiChiara J. Suarez T.A. Singla A. Tantry U.S. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. Platelets 2008 19 8 595 604 10.1080/09537100802351065 19012177
    [Google Scholar]
  12. Scott S.A. Sangkuhl K. Stein C.M. Hulot J-S. Mega J.L. Roden D.M. Klein T.E. Sabatine M.S. Johnson J.A. Shuldiner A.R. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 2013 94 3 317 323 10.1038/clpt.2013.105 23698643
    [Google Scholar]
  13. Park M.W. Her S.H. Kim C.J. SunCho J. Park G.M. Kim T.S. Choi Y.S. Park C.S. Koh Y.S. Park H.J. Kim P.J. Chung W.S. Seung K.B. Kim H.S. Shin J.G. Chang K. Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians. Genet. Med. 2016 18 8 833 841 10.1038/gim.2015.171 26699760
    [Google Scholar]
  14. Zhong Z. Hou J. Zhang Q. Li B. Li C. Liu Z. Yang M. Zhong W. He X. Wu H. Zhong M. Zhao P. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. Eur. J. Clin. Pharmacol. 2018 74 4 423 431 10.1007/s00228‑017‑2393‑1 29243114
    [Google Scholar]
  15. Sipeky C. Weber A. Szabo M. Melegh B.I. Janicsek I. Tarlos G. Szabo I. Sumegi K. Melegh B. High prevalence of CYP2C19*2 allele in Roma samples: Study on Roma and Hungarian population samples with review of the literature. Mol. Biol. Rep. 2013 40 8 4727 4735 10.1007/s11033‑013‑2569‑4 23645039
    [Google Scholar]
  16. Hasan M.S. Basri H.B. Hin L.P. Stanslas J. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: Why the Asian population requires special attention. Int. J. Neurosci. 2013 123 3 143 154 10.3109/00207454.2012.744308 23110469
    [Google Scholar]
  17. Plakogiannis F.A. Weidmann J. Fraser B. Kwong J. Asi D. Kumar P. Baldock M. Naamo J. Baluja R. Catanzariti R. Yeung S. Pont L. Williams K. De Rubis G. Dua K. Bukhari N.I. Investigation of smoking on the antiplatelet response to clopidogrel: Unravelling the smoker’s paradox. Pathol. Res. Pract. 2024 257 155290 10.1016/j.prp.2024.155290 38640781
    [Google Scholar]
  18. Crimi G. Somaschini A. Cattaneo M. Angiolillo D.J. Piscione F. Palmerini T. De Servi S. Cigarette smoking reduces platelet reactivity independently of clopidogrel treatment in patients with non-ST elevation acute coronary syndromes. Platelets 2018 29 3 309 311 10.1080/09537104.2017.1394452 29206072
    [Google Scholar]
  19. Edem E. Kirdök A.H. Kınay A.O. Tekin Ü.İ. Taş S. Alpaslan E. Pabuccu M.T. Akdeniz B. Does “smoker’s paradox” exist in clopidogrel-treated Turkish patients with acute coronary syndrome. Platelets 2016 27 3 240 244 10.3109/09537104.2015.1083544 26367336
    [Google Scholar]
  20. Amin A.M. Sheau Chin L. Azri Mohamed Noor D. SK Abdul Kader M.A. Kah Hay Y. Ibrahim B. The personalization of clopidogrel antiplatelet therapy: The role of integrative pharmacogenetics and pharmacometabolomics. Cardiol. Res. Pract. 2017 2017 1 17 10.1155/2017/8062796 28421156
    [Google Scholar]
  21. Nakazato R. Arsanjani R. Achenbach S. Gransar H. Cheng V.Y. Dunning A. Lin F.Y. Al-Mallah M. Budoff M.J. Callister T.Q. Chang H.J. Cademartiri F. Chinnaiyan K. Chow B.J.W. DeLago A. Hadamitzky M. Hausleiter J. Kaufmann P. Raff G. Shaw L.J. Villines T. Cury R.C. Feuchtner G. Kim Y.J. Leipsic J. Berman D.S. Min J.K. Age-related risk of major adverse cardiac event risk and coronary artery disease extent and severity by coronary CT angiography: Results from 15 187 patients from the International Multisite CONFIRM Study. Eur. Heart J. Cardiovasc. Imaging 2014 15 5 586 594 10.1093/ehjci/jet132 24714312
    [Google Scholar]
  22. Cavallari L.H. Lee C.R. Beitelshees A.L. Cooper-DeHoff R.M. Duarte J.D. Voora D. Kimmel S.E. McDonough C.W. Gong Y. Dave C.V. Pratt V.M. Alestock T.D. Anderson R.D. Alsip J. Ardati A.K. Brott B.C. Brown L. Chumnumwat S. Clare-Salzler M.J. Coons J.C. Denny J.C. Dillon C. Elsey A.R. Hamadeh I.S. Harada S. Hillegass W.B. Hines L. Horenstein R.B. Howell L.A. Jeng L.J.B. Kelemen M.D. Lee Y.M. Magvanjav O. Montasser M. Nelson D.R. Nutescu E.A. Nwaba D.C. Pakyz R.E. Palmer K. Peterson J.F. Pollin T.I. Quinn A.H. Robinson S.W. Schub J. Skaar T.C. Smith D.M. Sriramoju V.B. Starostik P. Stys T.P. Stevenson J.M. Varunok N. Vesely M.R. Wake D.T. Weck K.E. Weitzel K.W. Wilke R.A. Willig J. Zhao R.Y. Kreutz R.P. Stouffer G.A. Empey P.E. Limdi N.A. Shuldiner A.R. Winterstein A.G. Johnson J.A. Multisite investigation of outcomes with implementation] of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc. Interv. 2018 11 2 181 191 10.1016/j.jcin.2017.07.022 29102571
    [Google Scholar]
  23. Joo H.J. Ahn S.G. Park J.H. Park J.Y. Hong S.J. Kim S.Y. Choi W. Gwon H. Lim Y.H. Kim W. Kang W.C. Cho Y.H. Kim Y.H. Yoon J. Shin W. Hong M.K. Garg S. Jang Y. Lim D.S. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: A prospective multicentre registry study. Sci. Rep. 2018 8 1 1229 10.1038/s41598‑017‑18134‑y 29352151
    [Google Scholar]
  24. Frere C. Cuisset T. Quilici J. Camoin L. Carvajal J. Morange P.E. Lambert M. Juhan-Vague I. Bonnet J.L. Alessi M.C. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb. Haemost. 2007 98 10 838 843 10.1160/TH07‑04‑0296 17938809
    [Google Scholar]
  25. Biswas M. Kali S.K. Association of CYP2C19 loss-of-function alleles with major adverse cardiovascular events of clopidogrel in stable coronary artery disease patients undergoing percutaneous coronary intervention: Meta-analysis. Cardiovasc. Drugs Ther. 2021 35 6 1147 1159 10.1007/s10557‑021‑07142‑w 33523336
    [Google Scholar]
  26. Xi Z. Fang F. Wang J. AlHelal J. Zhou Y. Liu W. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis. Platelets 2019 30 2 229 240 10.1080/09537104.2017.1413178 29257922
    [Google Scholar]
  27. Dehbozorgi M. Kamalidehghan B. Hosseini I. Dehghanfard Z. Sangtarash M. Firoozi M. Ahmadipour F. Meng G. Houshmand M. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (806 C>T) alleles among an Iranian population of different ethnicities. Mol. Med. Rep. 2018 17 3 4195 4202 10.3892/mmr.2018.8377 29328413
    [Google Scholar]
/content/journals/chddt/10.2174/011871529X384209250812065418
Loading
CYP2C19 Genetic Variants Associated with Clopidogrel Resistance and Major Adverse Cardiovascular Events in Vietnamese Patients Undergoing Percutaneous Coronary Intervention
Bentham Science Publishers ; https://doi.org/10.2174/011871529X384209250812065418
/content/journals/chddt/10.2174/011871529X384209250812065418
/content/journals/chddt/10.2174/011871529X384209250812065418
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: cytochrome P-450 CYP2C19 ; Acute coronary syndrome ; clopidogrel ; percutaneous coronary intervention

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test